Viking Therapeutics Inc. Insider Trading

VKTX

Last 12 months

Insiders bought 150K and sold $18.3M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. President & CEO Brian Lian sold $7.69M on Jan 5, 8.5% of their stake, outside a plan.

Net open-market

−$18.2M

1 buy · 7 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 4

executives and directors

Last open-market buy

Mar 2026

Mar 10, 2026

Get an email when VKTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 29	Brian Lian President & CEO	SoldNo plan	148,517	$33.32	$4.95M	5.5%	Form 4
Jul 29	Greg Zante Chief Financial Officer	SoldNo plan	21,217	$33.47	710K	9.1%	Form 4
Jul 29	Marianna Mancini Chief Operating Officer	SoldNo plan	18,217	$33.47	610K	4.1%	Form 4
Mar 10	Neil William Aubuchon Chief Commercial Officer	Bought	4,475	$33.50	150K	New	Form 4
Jan 5	Greg Zante Chief Financial Officer	SoldNo plan 4 parts	57,661	$32.90 average	$1.9M	23%	Form 4
Jan 5	Marianna Mancini Chief Operating Officer	SoldNo plan 4 parts	57,661	$32.97 average	$1.9M	12%	Form 4
Jan 5	Brian Lian President & CEO	SoldNo plan 4 parts	233,409	$32.96 average	$7.69M	8.5%	Form 4
Jan 2	Matthew W Foehr Director	SoldNo plan	16,000	$35.11	562K	11%	Form 4
Oct 28, 2025	Marianna Mancini Chief Operating Officer	SoldNo plan	6,185	$35.00	216K	1.6%	Form 4
Oct 28, 2025	Brian Lian President & CEO	SoldNo plan	38,989	$35.01	$1.37M	1.6%	Form 4
Oct 28, 2025	Greg Zante Chief Financial Officer	SoldNo plan	6,185	$35.00	216K	3.4%	Form 4
Oct 27, 2025	Charles A Rowland Jr Director	SoldNo plan	60,000	$35.57	$2.13M	67%	Form 4
Jul 3, 2025	Brian Lian President & CEO	SoldNo plan	26,889	$27.80	748K	1.1%	Form 4
Jul 3, 2025	Greg Zante Chief Financial Officer	SoldNo plan	4,266	$27.76	118K	2.5%	Form 4
Jul 3, 2025	Marianna Mancini Chief Operating Officer	SoldNo plan	4,266	$27.77	118K	1.1%	Form 4
Mar 31, 2025	Sarah Kathryn Rouan Director	Bought	1,240	$24.15	30K	New	Form 4
Jan 6, 2025	Brian Lian President & CEO	SoldNo plan 2 parts	194,490	$42.74 average	$8.31M	7.6%	Form 4
Jan 6, 2025	Marianna Mancini Chief Operating Officer	SoldNo plan 2 parts	54,215	$42.75 average	$2.32M	13%	Form 4
Jan 6, 2025	Greg Zante Chief Financial Officer	SoldNo plan 2 parts	50,309	$42.75 average	$2.15M	23%	Form 4
Nov 8, 2024	Lawson Macartney Director	SoldNo plan	2,000	$68.67	137K	4.0%	Form 4

Jul 29No plan
Brian Lian
President & CEO · sold 148,517 at $33.32
$4.95M
5.5% of stake
Jul 29No plan
Greg Zante
Chief Financial Officer · sold 21,217 at $33.47
710K
9.1% of stake
Jul 29No plan
Marianna Mancini
Chief Operating Officer · sold 18,217 at $33.47
610K
4.1% of stake
Mar 10
Neil William Aubuchon
Chief Commercial Officer · bought 4,475 at $33.50
150K
New position
Jan 5No plan
Greg Zante
Chief Financial Officer · sold 57,661 at avg $32.90
$1.9M
23% of stake
Jan 5No plan
Marianna Mancini
Chief Operating Officer · sold 57,661 at avg $32.97
$1.9M
12% of stake
Jan 5No plan
Brian Lian
President & CEO · sold 233,409 at avg $32.96
$7.69M
8.5% of stake
Jan 2No plan
Matthew W Foehr
Director · sold 16,000 at $35.11
562K
11% of stake
Oct 28, 2025No plan
Marianna Mancini
Chief Operating Officer · sold 6,185 at $35.00
216K
1.6% of stake
Oct 28, 2025No plan
Brian Lian
President & CEO · sold 38,989 at $35.01
$1.37M
1.6% of stake
Oct 28, 2025No plan
Greg Zante
Chief Financial Officer · sold 6,185 at $35.00
216K
3.4% of stake
Oct 27, 2025No plan
Charles A Rowland Jr
Director · sold 60,000 at $35.57
$2.13M
67% of stake
Jul 3, 2025No plan
Brian Lian
President & CEO · sold 26,889 at $27.80
748K
1.1% of stake
Jul 3, 2025No plan
Greg Zante
Chief Financial Officer · sold 4,266 at $27.76
118K
2.5% of stake
Jul 3, 2025No plan
Marianna Mancini
Chief Operating Officer · sold 4,266 at $27.77
118K
1.1% of stake
Mar 31, 2025
Sarah Kathryn Rouan
Director · bought 1,240 at $24.15
30K
New position
Jan 6, 2025No plan
Brian Lian
President & CEO · sold 194,490 at avg $42.74
$8.31M
7.6% of stake
Jan 6, 2025No plan
Marianna Mancini
Chief Operating Officer · sold 54,215 at avg $42.75
$2.32M
13% of stake
Jan 6, 2025No plan
Greg Zante
Chief Financial Officer · sold 50,309 at avg $42.75
$2.15M
23% of stake
Nov 8, 2024No plan
Lawson Macartney
Director · sold 2,000 at $68.67
137K
4.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VKTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with VKTX

CompareIntrinsic value

AMRNAmarin Corp PLC\Uk

$12.11-4.95%46

WVEWave Life Sciences Ltd.

$3.59-1.10%40

RLYBRallybio Corporation

$15.54+0.84%62

KNSAKiniksa Pharmaceuticals International, plc

$92.24-5.45%71

ESPREsperion Therapeutics Inc.

No recent price50

JNJJohnson & Johnson

$273.20-0.73%53

CELUCelularity Inc.

$0.80-5.76%0

CYDYCytoDyn Inc.

$0.22-4.35%0

Held by ETFs

VKTX is in 62 US ETFs. The largest of them, with VKTX's weight in each:

Spot a number that looks wrong? Check it in VKTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VKTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.